Organon & Co (OGN)
Gross profit margin
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
---|---|---|---|---|
Gross profit | US$ in thousands | 1,677,000 | 2,023,000 | 2,141,000 |
Revenue | US$ in thousands | 6,263,000 | 6,174,000 | 6,304,000 |
Gross profit margin | 26.78% | 32.77% | 33.96% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $1,677,000K ÷ $6,263,000K
= 26.78%
The gross profit margin of Organon & Co. has shown a declining trend over the past five years, decreasing from 70.76% in 2019 to 59.84% in 2023. This indicates that the company's ability to generate profit from its sales revenue has been weakening over time. Factors such as changes in pricing strategies, cost structures, or competition may have contributed to this downward trend. It is important for management to closely monitor and analyze the drivers behind this decline to identify areas for improvement and to enhance the company's overall profitability in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Organon & Co
OGN
26.78%
Abbott Laboratories
ABT
20.40%
AbbVie Inc
ABBV
16.39%
Alkermes Plc
ALKS
39.97%
Amphastar P
AMPH
54.49%
ANI Pharmaceuticals Inc
ANIP
11.30%
Arcus Biosciences Inc
RCUS
-6.84%
Biomarin Pharmaceutical Inc
BMRN
78.31%
Bristol-Myers Squibb Company
BMY
37.71%
Catalent Inc
CTLT
21.75%
Catalyst Pharmaceuticals Inc
CPRX
45.19%